Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.67 |
| ▸ | CASP6 | P55212 | 13/20 | 0.67 |
| ▸ | CASP8 | Q14790 | 13/20 | 0.67 |
| ▸ | CASP1 | P29466 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247253 | 1.00 | CASP3 (0.67) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL645918 | 0.92 | CASP3 (0.57) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL7367055 | 0.92 | CASP3 (0.57) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL3056903 | 0.92 | CASP3 (0.57) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL18863053 | 0.90 | CASP3 (0.55) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL12946446 | 0.88 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL8402109 | 0.88 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL949009 | 0.88 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL13197161 | 0.88 | CASP1 (0.59) | CASP3CASP6CASP8CASP1 | |
| SCHEMBL647007 | 0.86 | CASP3 (0.50) | CASP3CASP6CASP8CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| WO-2006124477-A2 | COMBINATION THERAPY WITH INHIBITORS OF HMGB AND CASPASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-6620782-B1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-16 | — | — | US | disclosed |
| US-6620782-B1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP3 18/4885CASP6 22/4885CASP8 7/4885 |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | HMGB2, HMGB3, HMGB1 | CASP3 61/4885CASP6 18/4885CASP8 41/4885 |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP3 18/4885CASP6 22/4885CASP8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.